Agents currently in clinical trial for the treatment of PV: rusfertide, sapablursen, and bomedemstat

Ciro Rinaldi, MD, PhD, Lincoln County Hospital, Lincoln, UK, discusses recent advancements in the treatment of polycythemia vera (PV). This includes hepcidin mimetics rusfertide and sapablursen, and the lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.